Sheet _ 1 _ of _ 2

FORM PTO-1449

EPARTMENT OF COMMERCER 2 0

SERIAL NO. 09/818,875

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

TECH CENTER

Eric B. Kmiec et al.

FILING DATE March 27, 2001

GROUP 1635

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
Opp	5,565,350	10/15/96	Kmiec	435	172.3	···
	5,731,181	3/24/98	Kmiec	435	172.3	
	5,912,340	6/15/99	Kutyavin	536	24.5	
	6,004,804	12/21/99	Kumar	435	320.1	
ON	6,271,360	8/7/01	Metz	536	23.1	

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS							
EXAMINER MITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
$\mathcal{J}U$	WO 99/14226	3/25/99	PCT				
	WO 00/56748	9/28/00	PCT				
	WO 00/66604	11/9/00	PCT				
			1				<u></u>
			·				
		.^					
			,				<u> </u>
							·
				•			

EXAMINER

DATE CONSIDERED

EXAMINED: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

and a





Sheet 2 of 2

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OF ICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTY. DOCKET NO.
Napro-4

APPLICANT
Eric B. Kmiec et al.

FILING DATE
March 27, 2001

SERIAL NO.
09/818,875

GROUP
1635

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
EXAMINER INITIAL					
	Alexeev & Yoon, "Stable and inheritable changes in genotype and phenotype of albino melanocytes induced by an RNA-DNA oligonucleotide," Nature Biotech. 16:1343-1346 (1998)				
	Campbell et al., "Homologous recombination involving small single-stranded oligonucleotides in human cells," New Biologist 1:223-227 (1989)				
	Chan & Glazer, "Triplex DNA: fundamentals, advances, and potential applications for gene therapy," <u>J. Mol. Med.</u> 75:267-282 (1997)				
	Chan et al., "Targeted correction of an episomal gene in mammalian cells by a short DNA fragment tethered to a triplex-forming oligonucleotide," J. Biol. Chem. 274:11541-11548 (1999)				
	Cole-Strauss et al., "Correction of the mutation responsible for sickle cell anemia by an RNA-DNA oligonucleotide," Science 273:1386-1389 (1996)				
	Culver et al., "Correction of chromosomal point mutations in human cells with bifunctional oligonucleotides," Nat. Biotechnol. 17:989-993 (1999)				
	Gamper et al., "The DNA strand of chimeric RNA/DNA oligonucleotides can direct gene repair/conversion activity in mammalian and plant cell-free extracts," <u>Nucleic Acids Res.</u> 28:4332-4339 (2000)				
	Igoucheva et al., "Targeted gene correction by small single-stranded oligonucleotides in mammalian cells," Gene Therapy 8:391-399 (2001)				
	Kren et al., "Correction of the UDP-glucuronosyltransferase gene defect in the Gunn rat model of Crigler-Najjar syndrome type I with a chimeric oligonucleotide," Proc. Natl. Acad. Sci. USA 96:10349-10354 (1999)				
	Kunzelmann et al., "Gene targeting of CFTR DNA in CF epithelial cells," Gene Ther. 3:859-867 (1996)				
	Moerschell et al., "Transformation of yeast with synthetic oligonucleotides," <u>Proc. Natl. Acad. Sci. USA</u> 85:524-528 (1988)				
	Rando et al., "Rescue of dystrophin expression in <i>mdx</i> mouse muscle by RNA/DNA oligonucleotides," Proc. Natl. Acad. Sci. USA 97:5363-5368 (2000)				
	Vasquez et al., "Chromosomal mutations induced by triplex-forming oligonucleotides in mammalian cells," Nucl. Acids Res. 27:1176-1181 (1999)				
	Vasquez et al., "Specific mutations induced by triplex-forming oligonucleotides in mice," <u>Science</u> 290:530-532 (2000)				
	Yamamoto et al., "Strand-specificity in the transformation of yeast with synthetic oligonucleotides," Genetics 131:811-819 (1992)				
	Yanez & Porter, "Therapeutic gene targeting," Gene Therapy 5:149-159 (1998)				
	Xu et al., "Activation of human γ-globin gene expression via triplex-forming oligonucleotide (TFO)-directed mutations in the γ-globin gene 5' flanking region," Gene 242:219-228 (2000)				

EXAMINER

DATE CONSIDERED

5-15-03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.